Clinical and Biological Characterization of Patients with Low/Intermediate-1 Risk Myelodysplastic Syndrome and Iron Overload

被引：0

作者：

Ivars, David ^{[1
]}

Collado, Rosa ^{[2
]}

Alguero, Carmen ^{[1
]}

Carmen Tormos, M. ^{[1
]}

Diaz, Laura ^{[1
]}

Luis Garcia-Ghnenez, Jose ^{[3
]}

Arrizabalaga, Beatriz ^{[4
]}

Orero, Mayte ^{[2
]}

Perez, Pedro ^{[2
]}

Sanchez, Magdalena ^{[2
]}

Angeles Ruiz, M. ^{[5
]}

Yaguee, Nuria ^{[5
]}

Sancho-Tello, Reyes ^{[6
]}

Regadera, Ana ^{[7
]}

Tormo, Mar ^{[8
]}

Egea, Mercedes ^{[2
]}

Vidal, Elena ^{[2
]}

Enrique O'Connor, J. ^{[1
]}

Saez, Guillermo T. ^{[1
]}

Carbonell, Felix ^{[2
]}

机构：

[1] Univ Valencia, Valencia, Spain

[2] Hosp Gen Univ Valencia, Biomed Diag Ctr, Hematol Serv, Valencia, Spain

[3] Biomed Network Res Ctr Rare Dis, CIBERER, Valencia, Spain

[4] Hosp Cruces, Baracaldo, Spain

[5] Hosp Francesc de Borja, Valencia, Spain

[6] Hosp Arnau Vilanova, Hematol Serv, Valencia, Spain

[7] Hosp Gen Requena, Hematol Serv, Valencia, Spain

[8] Hosp Clin, Valencia, Spain

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.4956.4956

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4956

引用

页数：2

共 50 条

[41] Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome
Shenoy, Niraj
Vallumsetla, Nishanth
Rachmilewitz, Eliezer
Verma, Amit
Ginzburg, Yelena
BLOOD, 2014, 124 (06) : 873 - 881
[42] Azacitidine Is Effective in Patients with Low Intermediate-1 Risk Myelodysplastic Syndrome Managed in Community Based Practice: Preliminary Data From the Spanish Compassionate Use Registry
Garcia, Regina
de Miguel, Dunia
Bernal, Maria-Teresa
Tormo, Mar
Sanz, Guillermo
de Paz, Raquel
Figueredo, Antonio
Amutio, Maria E.
Guzman, Jose L.
BLOOD, 2009, 114 (22) : 1462 - 1462
[43] ANALYSIS OF SHORT-TERM EFFICACY OF LENALIDOMIDE IN PATIENTS WITH INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME WITHOUT 5Q DELETION
Yang, Y.
HAEMATOLOGICA, 2012, 97 : 582 - 582
[44] Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome
Zeidan, Amer M.
Pullarkat, Vinod A.
Komrokji, Rami S.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 117 : 57 - 66
[45] Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial
Komrokji, Rami S.
Al Ali, Najla H.
Padron, Eric
Cogle, Christopher
Tinsley, Sara
Sallman, David
Lancet, Jeffrey E.
Lis, Alan F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 251 - 254
[46] ELTROMBOPAG FOR THE TREATMENT OF THROMBOCYTOPENIA OF LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A PROSPECTIVE, RANDOMIZED, TRIAL
Oliva, E.
Santini, V.
Zini, G.
Palumbo, G.
Poloni, A.
Cortelezzi, A.
Rodeghiero, F.
Voso, M.
Molteni, A.
Sanpaolo, G.
Liberati, A.
Morabito, F.
Balleari, E.
Impera, S.
Salvi, F.
Spiriti, M.
Marino, A.
Roda, F.
Alati, C.
Ronco, F.
Raimondo, F.
Leoni, P.
Alimena, G.
Fioritoni, G.
Latagliata, R.
Nobile, F.
HAEMATOLOGICA, 2013, 98 : 456 - 456
[47] Eltrombopag for the treatment of thrombocytopenia of low and intermediate-1 IPSS risk myelodysplastic syndromes: Results of a prospective, randomized trial
Oliva, E. N.
Santini, V.
Zini, G.
Palumbo, G. A.
Poloni, A.
Cortelezzi, A.
Rodeghiero, F.
Voso, M. T.
Molteni, A.
Sanpaolo, G.
Liberati, M.
Morabito, F.
Balleari, E.
Impera, S.
Salvi, F.
Spiriti, M. A. Aloe
Marino, A.
Roda, F.
Alati, C.
Ronco, F.
Di Raimondo, F.
Leoni, P.
Alimena, G.
Latagliata, R.
Nobile, F.
LEUKEMIA RESEARCH, 2013, 37 : S162 - S162
[48] Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients
Bowen, DT
SEMINARS IN ONCOLOGY, 2005, 32 (04) : S16 - S23
[49] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality
Hironori Harada
Mitsumasa Watanabe
Kenshi Suzuki
Soshi Yanagita
Takahiro Suzuki
Yataro Yoshida
Akiro Kimura
Mitsuru Tsudo
Akira Matsuda
Kaoru Tohyama
Masafumi Taniwaki
Kenichi Takeshita
Masaaki Takatoku
Keiya Ozawa
International Journal of Hematology, 2009, 90 : 353 - 360
[50] Guidelines on iron chelation therapy in patients with myelodysplastic syndrome and transfusion iron overload
Gattermann, N.
LEUKEMIA RESEARCH, 2007, 31 : S15 - S16

← 1 2 3 4 5 →